medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2014, Number 5

Acta Pediatr Mex 2014; 35 (5)

Quantification of metformin and glyburide in blood for paediatric endocrinology

Alemón-Medina R, Chávez-Pacheco JL, Ramírez-Mendiola B, Rivera-Espinosa L, García-Álvarez R

Language: Spanish
References: 14
Page: 373-380
PDF size: 448.46 Kb.


ABSTRACT

Background: The recent use of antidiabetic drugs such as metformin and glyburide for the treatment and control of childhood obesity, insulin resistance and type II diabetes mellitus in children and adolescents, has encouraged physicians to determine plasma levels of these drugs for the right dose adjustment.
Objective: To implement and validate a UPLC-UV method to quantify metformin and glyburide in blood samples.
Materials and methods: Only a 0.1 mL-volume blood sample was used. Both drugs are removed by precipitation with methanol. Quantitation was carried out with mobile phase of 4.6 mM potassium phosphate monobasic (KH2PO4) 0.1 M pH = 6.5, sodium dodecyl sulphate (SDS) and acetonitrile (63:7:30), at 0.8 mL/min through a VARIAN Pursuit® C8 150 x 3.9 mm column at 40°C, 236 nm.
Results: The method allows the measurement of 20 to 600 nanograms of metformin and from 100 to 2 000 nanograms of glyburide per milliliter of blood. Both drugs are physicochemically stable in blood samples for up to 30 days at 4°C.
Conclusion: Our method allows quantification of metformin and glyburide in paediatric blood samples, to support the clinicians to monitor treatment compliance, bioavailability and pharmacokinetic profiles.


REFERENCES

  1. Ventura EE, Davis JN, Alexander KE, Shaibi GQ, Lee W, Byrd-Williams CE, et al. Dietary intake and the metabolic syndrome in overweight latino children. J Am Diet Assoc 2008;108(8):1355-9. doi: 10.1016/j.jada.2008.05.006.

  2. Raj M. & RK. Kumar Obesity in children & adolescents. Indian J Med Res 2010;132:598–607.

  3. Encuesta Nacional de Salud y Nutrición, 2012. Secretaría de Salud, México. ENSANUT, 2012.

  4. Loannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs 2005;65(10):1391–1418.

  5. Kanekara A, Sharma M. Pharmacological Approaches for Management of Child and Adolescent Obesity. J Clin Med Res 2010;2(3):105-11. doi: 10.4021/ jocmr2010.05.288w.

  6. De Silva-Sanigorski A, L. Prosser, L. Carpenter, S. Honisett, L. Gibbs, M. Moodie, et al. Evaluation of the childhood obesity prevention program Kids - ‘Go for your life’. BMC Public Health 2010;10:288.

  7. Lenzen S, Lortz S, Tiedge M. Effect of metformin on SGLT1, GLUT2, and GLUT5 hexose transporter gene expression in small intestine from rats. Biochem Pharmacol 1996;51:893–896.

  8. Fulgencio JP, Kohl C, Girard J, Pegorier JP. Effect of metformin on fatty acid and glucose metabolism in freshly isolated hepatocytes and on specific gene expression in cultured hepatocytes. Biochem. Pharmacol 2001;62:439– 446.

  9. Masharani U., Karam JH. & German MS. Hormonas pancreáticas y diabetes mellitus. En: Endocrinología básica y clínica de Greenspan. Ciudad de México: El Manual Moderno, 2008; pp. 693-786.

  10. Kendall DL, Amin R & Clayton PE. Metformin in the treatment of obese children and adolescents at risk of type 2 diabetes. Pediatr Drugs 2014;16:13-20.

  11. American Diabetes Association. Type 2 diabetes in children and adolescents. Pediatrics 2014;105:671-680.

  12. Sohrabi MR, N. Kamali & M. Khakpour. Simultaneous spectrophotometric determination of metformin hydrochloride and glibenclamide in binary mixtures using combined discrete and continuous wavelet transforms. Analytical Sciences 2011:27:1037-1041.

  13. Abu Ruz S, J. Millership, J. McElnay J. The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide or glimperide in plasma. Chromatography B 2005;817:277-286.

  14. Malleswararao CSN., M.V. Suryanarayana & K. Mukkanti. Scientia Pharmaceutica 2002;80:139-152.




2020     |     www.medigraphic.com